Mangoceuticals, EBITDA from 2010 to 2024
| MGRX Stock | 2.37 0.14 5.58% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -9.2 M | Current Value -8.7 M | Quarterly Volatility 3.1 M |
Check Mangoceuticals, Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mangoceuticals, Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.4 K, Interest Expense of 0.0 or Selling General Administrative of 6.8 M, as well as many indicators such as Price To Sales Ratio of 115, Dividend Yield of 0.0 or PTB Ratio of 120. Mangoceuticals, financial statements analysis is a perfect complement when working with Mangoceuticals, Common Valuation or Volatility modules.
Mangoceuticals, |
Latest Mangoceuticals, Common's EBITDA Growth Pattern
Below is the plot of the Ebitda of Mangoceuticals, Common Stock over the last few years. It is Mangoceuticals, Common's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mangoceuticals, Common's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.19 M) | 10 Years Trend |
|
Ebitda |
| Timeline |
Mangoceuticals, EBITDA Regression Statistics
| Arithmetic Mean | (1,341,751) | |
| Coefficient Of Variation | (233.80) | |
| Mean Deviation | 2,118,769 | |
| Median | (17,520) | |
| Standard Deviation | 3,136,968 | |
| Sample Variance | 9.8T | |
| Range | 9.2M | |
| R-Value | (0.64) | |
| Mean Square Error | 6.2T | |
| R-Squared | 0.41 | |
| Significance | 0.01 | |
| Slope | (449,740) | |
| Total Sum of Squares | 137.8T |
Mangoceuticals, EBITDA History
About Mangoceuticals, Common Financial Statements
Mangoceuticals, Common investors use historical fundamental indicators, such as Mangoceuticals, Common's EBITDA, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mangoceuticals, Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBITDA | -9.2 M | -8.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| V | Visa Class A | |
| MSFT | Microsoft |
Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.